IPP Bureau
Briefs: Dr. Reddy's Laboratories and Max Healthcare Institute
By IPP Bureau - May 15, 2023
Dr. Reddy's Laboratories has been issued a Form 483 with four observations
Dr. Lal Path Labs posts Q4 FY23 consolidated PAT at Rs. 56.7 Cr
By IPP Bureau - May 13, 2023
Dr. Lal Path Labs has reported total income of Rs. 505.2 crores during the period ended March 31, 2023
Alembic Q4 FY23 consolidated PAT up at Rs. 48.25 Cr
By IPP Bureau - May 13, 2023
Alembic has reported total income of Rs. 39.15 crores during the period ended March 31, 2023
Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr
By IPP Bureau - May 13, 2023
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
USFDA approves Astellas' Veozah’ for treatment of vasomotor symptoms due to menopause
By IPP Bureau - May 13, 2023
VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause
Nippon Express Italia receives IATA CEIV Pharma Certification for Its Facility near Milan Malpensa Airport
By IPP Bureau - May 13, 2023
Milan is also an important hub for the distribution of pharmaceuticals to the rest of Europe
Sanofi India to demerge healthcare businesses
By IPP Bureau - May 12, 2023
This decision will accelerate growth for both its pharma & consumer healthcare businesses in India
Bliss GVS Pharma Q4 FY2023 consolidated PAT drops at Rs. 3.34 Cr
By IPP Bureau - May 12, 2023
The company has reported total income of Rs. 187.75 crores during the period ended March 31, 2023
Lilly allocates additional US $50 million to Social Impact Venture Capital portfolio
By IPP Bureau - May 12, 2023
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
USFDA approves GSK’s respiratory syncytial virus vaccine ‘Arexvy’
By IPP Bureau - May 12, 2023
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
Gilead acquires XinThera to strengthen pipeline in oncology
By IPP Bureau - May 12, 2023
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Takeda pledges support to HAE patients through its ‘Sunrise patient support program’
By IPP Bureau - May 11, 2023
Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support
AIIA and CCRAS jointly organised session for research and education in Ayush
By IPP Bureau - May 11, 2023
Pandemic was the opportunity for Ayush to develop their science and Ayush did it by developing Ayush 64, etc
Orchid Pharma Q4 FY23 consolidated PAT up at Rs. 59.13 Cr
By IPP Bureau - May 11, 2023
The company has reported total income of Rs. 211.62 crores during the period ended March 31, 2023
Evonik partners with Safic-Alcan to boost offering of advanced food ingredients
By IPP Bureau - May 11, 2023
Wider reach for nutraceuticals portfolio in Europe, Turkey and Egypt
